Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.36p +3.59% 10.40p 10.20p 10.52p 10.72p 10.00p 10.10p 8,644,597 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 323.14

Oxford Biomedica PLC Total Voting Rights

01/12/2017 10:16am

UK Regulatory (RNS & others)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart

2 Months : From Nov 2017 to Jan 2018

Click Here for more Oxford Biomedica Charts.


RNS Number : 1367Y

Oxford Biomedica PLC

01 December 2017

Oxford BioMedica

Total Voting Rights

Oxford, UK - 1 December 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 November 2017 consisted of 3,107,136,542 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 3,107,136,542.

The above figure (3,107,136,542) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.

- Ends -

 For further information, please 
  Oxford BioMedica plc:                       Tel: +44 (0)1865 
   John Dawson, Chief Executive Officer        783 000 
   Stuart Paynter, Chief Financial 
  Consilium Strategic Communications          Tel: +44 (0)20 
   Mary-Jane Elliott/Matthew Neal/Philippa     3709 5700 
   Gardner/Laura Thornton 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at

This information is provided by RNS

The company news service from the London Stock Exchange



(END) Dow Jones Newswires

December 01, 2017 05:16 ET (10:16 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:gb D:20180120 20:38:24